Trial Profile
A study to compare the use of low-dose liraglutide in patients without a diagnosis for type 2 diabetes to the other GLP-1 receptor agonists (GLP-1 RAs, albiglutide, dulaglutide, and exenatide)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2017
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary) ; Albiglutide; Dulaglutide; Exenatide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 Oct 2017 New trial record
- 12 Oct 2017 Results presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research